Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver Metastases Demonstrates Therapeutic …GlobeNewswire (press release)SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”), cellular th… Continue reading
|
Sorrento Therapeutics Autologous Anti-CEA CAR–T Cell Therapy for Liver Metastases Demonstrates Therapeutic …
GlobeNewswire (press release) SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”), cellular therapy focused subsidiary, TNK Therapeutics, Inc. (“TNK”), and Surefire Medical, Inc., announced today initial results from the Hepatic … Sorrento (SRNE) Says Anti-CEA CAR–T Cell Therapy for Liver Metastases Demonstrates Therapeutic Activity in Stage …StreetInsider.com Sorrento’s liver artery-infused CAR–T cells showed positive effect in early-stage studySeeking Alpha |
STLtoday.com |
First childhood leukemia patient ready for ‘game-changing’ therapy in St. Louis
STLtoday.com Jonathan Cook, 12, of Swansea, Ill., relaxes in his hospital bed during an interview on Tuesday , Feb. 27, 2018, at St. Louis Children’s Hospital. Jonathan will be the first to receive CAR–T cell therapy for recurring leukemia at Children’s Hospital … |
Immuno-Oncology News |
Fate Receives $4 Million to Advance Natural Killer Cell Immunotherapy Into Trials
Immuno-Oncology News At the heart of Fate’s therapy is engineering white blood cells known as natural killer cells to do a better job of killing tumor cells. Natural killer cells play a key role in preventing and eliminating tumor cells. Once immune system antibodies bind … |
Xconomy |
Paying for Gene Therapy, CRISPR in People, RNAi at “What’s Hot” on May 16
Xconomy The first U.S. gene therapy, for a rare form of vision loss, is now on the market. In 2017, the FDA also approved the first two CAR-T cell therapies for cancer, the first cancer drug based on a genetic signature, and the first smartphone app to treat … |